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The UK Children’s Cancer Study Group (UKCCSG), established in 1977, provides a highly organised structure for both service
provision and research, and represents the model to which the adult cancer community is currently aspiring. Since childhood cancer is
so rare, it is both essential and feasible for the vast majority of children to be referred into the network of specialist centres, and also
for the maximum number of children to be recruited into national and international clinical trials. Over the last 30–40 years there
have been major advances in treatment, such that now approximately 70% of children diagnosed with cancer will be cured of their
disease. The conduct of clinical trials in this patient population does, however, raise a number of specific issues and these are
discussed in the paper.
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Childhood cancer is rare. There are approximately 1500 newly
diagnosed cases each year in the UK, up to age 15 years. Over the
last 30–40 years there have been major advances in treatment, and
now approximately 70% of children diagnosed with cancer will be
cured of their disease. When this small overall number of cases is
broken down by tumour type and prognostic factors (such as age
or stage of disease), the planning of clinical trials can become very
difficult. Despite this, 70% of all children are currently on such
trials, which are coordinated either by the UK Children’s Cancer
Study Group (UKCCSg) (solid tumours) or the Medical Research
Council (leukaemia) (see Table 1).
TRIAL ACTIVITY
Since 1977 there has been a close-knit network of specialist
treatment centres. There are now 22 of these in the British Isles and
Ireland. These are all within NHS hospitals and are designated
‘UKCCSG centres’. All are recognised as centres of excellence for
the treatment of children with cancer. This highly organised
structure for care and research is a model to which the adult cancer
community is currently aspiring through both the Calman
reshaping and the National Cancer Research Network (NCRN).
All of the activities of the UKCCSG are coordinated through the
Data Centre in Leicester. Since childhood cancer is so rare, it is
both essential and feasible for the vast majority of children with
cancer to be referred to these specialist centres. Currently, around
90% of all children with cancer are treated by clinicians who are
individual members of the UKCCSG. This percentage has
increased steadily since the formation of the Group in 1977. At
that stage, with fewer centres in place, only about 43% of children
were treated in specialist centres (see Figure 1).
The research and clinical trials activity of the Group is organised
through the national structure and networks. There is a
comprehensive portfolio of trials, phases I, II and III, all conducted
on a multicentre basis. At any time, there will be about 30 trials
open to recruitment, 10 closed to recruitment but still on active
follow-up, and around 20 in advanced or early stages of planning.
The last decade has seen a major increase in international
collaboration. In some cases, this will mean that the UKCCSG
takes a leading role in coordinating the trial, perhaps on behalf of
SIOP (International Paediatric Oncology Society). In others, the
collaboration may take the form of a partnership with another
national group or organisation, such as SFOP (French Paediatric
Oncology Society). Arrangements for overall trial coordination will
vary from trial to trial. Only by combining forces to run
international trials it is possible to conduct randomised trials in
an acceptable time-frame, and with sufficient power to answer the
study question.
Largely because of small patient numbers there is a limit to the
number of early drug trials that can be run at any one time. To
facilitate those trials, within the 22 UKCCSG centres there are 12
dedicated ‘phase I centres’. These must fulfil certain criteria to be
able to participate in phase I trials (i.e. a committed clinician, a
research nurse in post, and ability to comply with the urgent
reporting and Case Report Form completion). Problems of
recruitment to these early drug trials led to a decision in 1996 by
the UKCCSG New Agents Group to enter into discussions with
colleagues from the French Pharmacology Group. A very success-
ful alliance has resulted from those early discussions, leading to
joint phase II and I studies. The infrastructure in place within the
UKCCSG Data Centre has led to it taking the main coordinating
role for these studies. The alliance has recently been extended to
include colleagues in Germany and The Netherlands with the
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lcreation of a European New Agents Group (EURONAG). For
company-led or-supported phase I/II trials, the issues concerning
recruitment are likely to be different. Financial constraints will
influence the number of centres to be initiated and opened.
Ensuring that every eligible patient is considered for entry on trial
is crucial, so the use of screening logs has increased and is now
routine in phase I trials. In this way, it is possible to monitor the
reasons why some patients are not going into the trial. This may be
due to lack of ethics approval, patients not fulfilling completely the
eligibility criteria, or consent not being given. If recruitment is
particularly slow, it may be necessary to re-examine the eligibility
and exclusion criteria.
Table 1 Percentage of UKCCSG patients entered in national and international trials. Analysis by diagnostic
group
Diagnostic group Years Trials % entered
Acute lymphoblastic 1977–79 UKALL V–VII
a 61




1991–96 UKALL XI and Infant ALL
b 84
1997–99 ALL 97 and Infant ALL
b 85
Acute nonlymphocytic 1977–79 UKAML 43
leukaemia 1980–82 AML 8 46
1983–87 Joint AML, AML 9 39
1988–94 AML 10 64
1995–99 AML 12 76
Hodgkin’s disease 1982–91 8201 76
1992–99 9201 79
NHL 1977–84 7701 54
1985–89 8501–8503 65
1990–95 9001–9004 81
1996–99 9503, 9601–9603 66
PNET 1979–82 7801 44
1985–88 SIOP 31
1992–99 PNET–3 and Infant 59
Neuroblastoma 1982–89 ENSG Survey 83
1990–99 ENSG 5–9, LNESG 77
Wilms’ tumour 1980–85 8001 89
(incl. rhabdoid and BMRTC) 1986–91 8601 92
1992–99 9101 95
Liver tumour 1990–93 SIOPEL–1 88
1996–99 SIOPEL–2,3 84
Osteosarcoma 1983–85 EORTC 83 43
1986–92 EORTC 86 49
1993–99 EORTC 93 51
Ewing’s sarcoma 1979–85 7802 61
1986–92 8701 75
1993–99 EICESS 78
Rhabdomyosarcoma 1985–88 IRS–3 21
1989–94 MMT–89 76
1995–99 MMT–95 79
All other soft tissue 1989–94 MMT–89 41
sarcoma 1995–99 MMT–95 52
Malignant non-CNS 1979–88 7901 70
germ–cell 1989–99 8901 88
CNS germ-cell 1989–95 8901 47
aIncluding NHL trials for T-ALL.
bIncluding NHL trials for B-ALL.
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As the UKCCSG has grown in size and scope of its activities, there
has been continuous refinement of the organisational structure
essential to its efficient management and coordination. The
Executive Committee has overall responsibility for the activities
of the Group, supported by the only permanent member – the
Executive Director of the Data Centre. Members of the Executive,
including the three Officers (Chairman, Treasurer and Secretary)
are elected from among the membership and serve a period of 3
years.
Day-to-day development of clinical trial protocols and other
trial-related activity is through the various working groups,
representing all the tumour types and disciplines. Working Group
Chairs serve for a period of 5 years and membership of the groups
is regularly reviewed to maintain a balance of experience and new
blood.
Central to the functioning of the UKCCSG is the Data Centre,
based in the University of Leicester. Through here all the
administration of the Group, as well as the national Register of
Childhood Cancer, all the clinical trials, and the range of other
activities, are coordinated.
Within each UKCCSG centre, there is a named clinician who
functions as ‘centre coordinator’ and whose main role is to act as a
conduit for communication both to and from colleagues in the
centre. Since 1990, data managers funded by the Cancer Research
Campaign (now Cancer Research UK) have been employed in
centres to facilitate collection of both trial and registry data. In
recent years, there has been a considerable increase in the number
of research nurses being appointed in the centres. Mainly financed
by departmental research funds, these nurses have developed a
very varied and essential role across all the trial activity of the
UKCCSG (see Figure 2).
TRIAL DEVELOPMENT AND EXECUTION
New studies are developed through the tumour working groups
including all international collaborative studies (Figure 3).
For all trials there is a two-tier protocol approval process, which
means that a protocol is first considered at one of the twice yearly
national meetings as a concept and if approved, it is fully
developed and submitted for final approval at the next meeting 6
months later. At both the concept and final approval stage, all
UKCCSG members have the opportunity to discuss and make
comment through their centre coordinator For industry trials,
particularly where registration is an issue, this time-frame for
approval is not always acceptable. It was, therefore, agreed that
phase I trials may fast-track through the system so that once
approved by the New Agents Group, they only have to come for
discussion once with the national groups, thereby cutting down
quite significantly on the protocol development and start up time
for new phase I trials (see Figure 3).
The process of obtaining ethical approval can represent a source
of potential, and sometimes significant, delay in study start up
(Pinkerton et al (2002) Eur J Cancer 38: 1051–1058). Bearing in
mind that all UKCCSG trials, including phase I, will be multicentre,
there is a need to obtain both national and local ethics committee
approval and that will take, at best, several months before all
centres are able to start recruiting patients. In the meantime,
eligible trial patients may be missed.
For the UKCCSG, an average of six to eight protocols a year are
opened. In the past, the principal investigator, a busy clinician, not
necessarily experienced in preparing such applications, submitted
the application to their nearest Multi-Centre Research Ethics
Committee (MREC). It became clear that protocols were often
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Figure 3 Trial development and approval.
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lgiven final approval by UKCCSG, but there was a long delay in
submission to, and then approval by, MREC. Moreover, protocols
were being submitted to the MREC in the region where the
principal investigator was based, so that in the course of 1 year,
there might have been one protocol considered at almost every
MREC in the country. This was inefficient, from both the
UKCCSG’s and the Ethics Committee’s perspective. Following
discussions with Central Office for Research Ethics Committees
(COREC), it was agreed that the national group could submit all
protocols centrally, and to the same MREC. The applications are
now prepared by the Executive Director in the Data Centre and
submitted to one MREC. This new system is working well and start
up times for studies are already much reduced.
Once the trial is open, data quality and trial form return rate are
reviewed on an ongoing basis by staff in the Data Centre (trial
coordinator and statistician assigned to a particular trial). Further
clinical checking, and particularly adherence to protocol, is carried
out by the study (clinical) coordinator during regular visits to the
Data Centre. A facility to check and raise queries on-line will soon
be available with the introduction of the first trials to be run via
remote data entry. Currently, source data verification is carried out
by site monitoring for phase I trials only.
The study coordinator(s), or lead investigator(s) for any
particular study also act as a main point of contact, either by
telephone or e-mail, for discussion about difficult cases. Where
there is a query related to imaging or pathology, for instance, then
the lead radiologist or pathologist on the working group is
consulted. Issues around chemotherapy may lead to contact with
the pharmacist on the group, or reference to the UKCCSG
Chemotherapy Standardisation Group (see Figure 4).
INFORMING THE PARTICIPANTS
Parent/Patient Information Sheets are now a crucial part of any
treatment protocol, and are an area on which the ethics
committees place a great deal of importance. Providing clear and
detailed information can help in reassuring both parents and
children about the safety of the trial. Provision of such information
to parents and patients is a major issue. Under the new (1998) Data
Protection Act, it is a legal requirement in order that consent can
be considered to be truly informed. To ensure that the information
provided about the safety and nature of the trial is clear, a first
requirement is that the language should be appropriate, whether
the information is being given orally or in writing, and if necessary
translated into another language. In practice, the information is
given both orally and in writing, and on a number of separate
occasions. Timing of conveying any information to families and
patients can be critical. Of particular difficulty may be the study
design requiring day 1 randomisation when the clinician has just
met the family, has to explain that their child has cancer, invite
participation into a clinical trial, and then raise the question of
randomisation. Much of the terminology used will be completely
unfamiliar at this stage. Care must be taken to avoid information
overload, and to ensure that the situation is handled in the most
sympathetic and effective way possible.
A template Patient Information Sheet has been produced for use
with all MREC submissions and plans to develop a similar template
for children are underway. The guidelines for preparation of
Patient Information Sheets for children in the UK include the need
for age-specific Patient Information Sheets. Three of these are now
required: one for children aged 14þ years (the wording of which
will be almost identical to that for the parents); one for children
aged 8–14 years (with appropriate wording); and a third for
children under the age of 8 years, with the expectation that this will
be read to the child by the parent or guardian. The latter may
include pictures, if relevant and appropriate. Devising these for
some of the particularly complex protocols is proving especially
challenging. Where eligibility includes young adults, who are
legally able to consent for themselves (over 18 years in England,
Wales and Northern Ireland, and over 16 years in Scotland),
further information sheets/consent forms are required.
Both the wording of the information, and the way it is
communicated to the parents or patients, may have an impact
on whether or not they decide to participate in a trial. Sufficient
time must be allowed for this procedure in the centre. The
arrangements in the centres will vary, but it is likely to be both the
clinician and the research nurse who are involved in this process.
For the phase I and II studies, the role of the local research nurse
is crucial. The relationship with the parents and children is one
that is built on trust, and that may have been developed over a
considerable time. It is important that there is honesty about the
risks or hazards that may be involved with any trial. The parent or
child needs time to absorb the information given, and to ask
questions, either at the time, or later, and clear contact details must
be provided. They need to fully understand that participation is
voluntary, and that they are free to withdraw at any time without
jeopardising either their future treatment or the relationship with
the doctor or team. Further reassurance about safety in the trial
can be given by reference to the very close monitoring that will
take place, particularly of any serious toxicities reported, and that
if necessary the trial could be stopped early. Parents and children
need to know that they will be kept informed of any significant
developments within the trial that may affect safety.
One of the main difficulties about providing information in this
setting, and ensuring that it is fully absorbed, is that it is often
being delivered at a time of maximum stress for the families. To try
and ensure that information is readily available at any time, the
UKCCSG now produces a quarterly magazine for families of
children and young people with cancer. Produced now in
collaboration with the National Alliance of Childhood Cancer
Parent Organisations (NACCPO), Contact represents a very
positive example of professionals and parents working together.
One of the primary aims of the magazine is the provision of good
and reliable information, on a whole range of topics. The content
takes account of the fact that the readers will include the newly
diagnosed, those at the palliative care stage, the recently or the not
so recently bereaved parents, extended family and friends, as well
as health-care professionals and the general public. The articles are
written for the lay person, and with 9000 copies per issue being
distributed and available in each centre, wide national coverage is
ensured. Contact is now also available on the web (www.ukccsg.
org/contact_magazine.htm). This magazine has enabled the
UKCCSG to flag up the importance of research and specific trial-
related matters, such as the different phases of clinical trials, and
the aims and particular issues surrounding each. Reader feedback
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Figure 4 List of UKCCSG Working Groups.>
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lhas confirmed that these are the sort of articles that readers find
interesting and helpful. The hope is that by providing clear and
detailed information, and taking time to discuss it thoroughly,
parents or children will be enthusiastic to participate in clinical
trials.
FUNDING OF ACTIVITY
The UKCCSG receives no permanent funding. Running costs of all
of the activities conducted under the umbrella of the UKCCSG now
exceed d1.25 million a year. Of this, grant income makes up about
three-quarters, with the remainder from charitable donations,
pharmaceutical company-sponsored trials, and a levy paid by each
of the centres in relation to research activity undertaken in each
centre. The main source of grant income has for many years been
The Cancer Research Campaign (now Cancer Research UK) both
in the form of peer reviewed core funding and specific project
grants. Grants are also obtained from a number of smaller
charities.
CONCLUSION
Overall referral into specialist centres for children with cancer,
and recruitment into clinical trials is very high and exceeds
considerably the targets currently being set for the NCRN
for the adult cancer trials in the UK. There are, however, still
tumour types (e.g. brain tumours) and age groups (e.g.
adolescents), where centralised care is less well organised and
trial recruitment remains low. There is also some variation
between centres in terms of facilities, staffing and independent
funding, which may lead to differences in recruitment to trials and
biological studies in particular. There also remain issues about UK
randomisation rates to certain studies in comparison with other
European centres.
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